175 related articles for article (PubMed ID: 34814035)
1. Effectiveness of lacosamide in children and young adults previously treated with other sodium channel blockers.
Suzuki T; Natsume J; Kumai S; Maki Y; Yamamoto H; Numoto S; Narahara S; Kubota T; Tsuji T; Kato T; Yamada K; Maruyama K; Okumura A; Takahashi Y; Kidokoro H
Epilepsy Behav; 2021 Dec; 125():108397. PubMed ID: 34814035
[TBL] [Abstract][Full Text] [Related]
2. Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort.
McGinnis E; Kessler SK
Epilepsia; 2016 Sep; 57(9):1416-25. PubMed ID: 27430392
[TBL] [Abstract][Full Text] [Related]
3. Switching from traditional sodium channel blockers to lacosamide in patients with epilepsy.
Kim DW; Kim HK; Bae EK
Seizure; 2019 Feb; 65():172-175. PubMed ID: 30721874
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs.
Neal A; D'Souza W; Hepworth G; Lawn N; Cook M; Nikpour A
Epilepsy Behav; 2018 Mar; 80():25-32. PubMed ID: 29396359
[TBL] [Abstract][Full Text] [Related]
5. Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy.
Baulac M; Byrnes W; Williams P; Borghs S; Webster E; De Backer M; Dedeken P
Acta Neurol Scand; 2017 Apr; 135(4):434-441. PubMed ID: 27714769
[TBL] [Abstract][Full Text] [Related]
6. Lacosamide tolerability in adult patients with partial-onset seizures: Impact of planned reduction and mechanism of action of concomitant antiepileptic drugs.
Foldvary-Schaefer N; Fong JS; Morrison S; Wang L; Bena J
Epilepsy Behav; 2016 Apr; 57(Pt A):155-160. PubMed ID: 26956629
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive lacosamide in clinical practice: sodium blockade with a difference?
Stephen LJ; Kelly K; Parker P; Brodie MJ
Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421
[TBL] [Abstract][Full Text] [Related]
8. Lacosamide in patients with intellectual disability and refractory epilepsy.
Kleist A; Kerling F; Hamer H; Winterholler M
Acta Neurol Belg; 2019 Sep; 119(3):423-430. PubMed ID: 30840220
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of immediate switch from sodium channel blockers to Lacosamide.
Talha Özgün O; Kandemir Yılmaz M; Mert Atmaca M; Keskin Güler S; Buluş E; Duman A; Çelebi Ö; Gürses C
Epilepsy Behav; 2023 Aug; 145():109355. PubMed ID: 37473655
[TBL] [Abstract][Full Text] [Related]
10. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
11. Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: A long-term study of 136 patients.
Böttcher S; Lutz MT; Mayer T
Epilepsia; 2017 Oct; 58(10):1749-1754. PubMed ID: 28804872
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study.
Ishikawa N; Eguchi Y; Izumo H; Tateishi Y; Tani H; Kobayashi Y; Okada S
Epilepsy Behav; 2022 Apr; 129():108614. PubMed ID: 35203014
[TBL] [Abstract][Full Text] [Related]
13. Sodium channel blockers are effective for benign infantile epilepsy.
Numoto S; Kurahashi H; Takagi M; Azuma Y; Iwayama H; Okumura A
Seizure; 2021 Nov; 92():207-210. PubMed ID: 34592700
[TBL] [Abstract][Full Text] [Related]
14. Use of lacosamide in children: experience of a tertiary medical care center in Brazil.
Romão TT; Angelim AIM; Prado HJPD; Goes FV; Pires MEP; Fontana RDS; Pires LC; Fernandes AR; D'Andrea-Meira I
Arq Neuropsiquiatr; 2022 Nov; 80(11):1090-1096. PubMed ID: 36577407
[TBL] [Abstract][Full Text] [Related]
15. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.
Sake JK; Hebert D; Isojärvi J; Doty P; De Backer M; Davies K; Eggert-Formella A; Zackheim J
CNS Drugs; 2010 Dec; 24(12):1055-68. PubMed ID: 21090839
[TBL] [Abstract][Full Text] [Related]
16. Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior.
Zhou R; Qu R; Liu M; Huang DP; Zhou JY; Chen Y; Chen XQ
Epilepsy Behav; 2023 Sep; 146():109353. PubMed ID: 37481960
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients with severely refractory epilepsies - A monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center.
Kurth C; Kockelmann E; Steinhoff BJ
Seizure; 2017 Feb; 45():47-51. PubMed ID: 27915111
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region.
Arabi M; Alsaadi T; Nasreddine W; Al-Hashel J; Dirani M; Beydoun A
Epilepsy Behav; 2018 Jul; 84():118-121. PubMed ID: 29778846
[TBL] [Abstract][Full Text] [Related]
19. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA.
Villanueva V; López-Gomáriz E; López-Trigo J; Palau J; García M; Villarroya T; Bonet M; Santafé C
Epilepsy Behav; 2012 Mar; 23(3):298-304. PubMed ID: 22370116
[TBL] [Abstract][Full Text] [Related]
20. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice.
Wu T; Chuang YC; Huang HC; Lim SN; Hsieh PF; Lee WT; Cheng MY; Tsai MH; Jou SB; Chang CW; Hsieh HY; Du X; Hellot S; McClung C; Hung C
Epilepsy Behav; 2020 Dec; 113():107464. PubMed ID: 33152580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
